

David Back

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5927852/publications.pdf>

Version: 2024-02-01

62
papers

2,715
citations

186209

28
h-index

182361

51
g-index

81
all docs

81
docs citations

81
times ranked

3041
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Prescribing Nirmatrelvir/Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746. | 2.0 | 35 |
| 2 | COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 212-213. | 1.1 | 20 |
| 3 | The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 292-302. | 1.5 | 7 |
| 4 | Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021, 21, 9-27. | 1.1 | 31 |
| 5 | Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374. | 2.7 | 17 |
| 6 | Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3417-3424. | 1.3 | 30 |
| 7 | Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086. | 1.3 | 43 |
| 8 | Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa040. | 0.4 | 17 |
| 9 | The challenge of HIV treatment in an era of polypharmacy. <i>Journal of the International AIDS Society</i> , 2020, 23, e25449. | 1.2 | 107 |
| 10 | Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±aribavirin in hepatitis C virus genotype 1 and 4 infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. <i>Journal of Viral Hepatitis</i> , 2019, 26, 685-696. | 1.0 | 11 |
| 11 | Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Infectious Diseases</i> , 2019, 219, 1735-1742. | 1.9 | 40 |
| 12 | Antiretroviral drug-drug interactions in an era of polypharmacy. <i>Germs</i> , 2019, 9, 123-124. | 0.5 | 0 |
| 13 | Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 961-971. | 1.1 | 3 |
| 14 | Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. <i>HIV Clinical Trials</i> , 2018, 19, 31-37. | 2.0 | 2 |
| 15 | Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw485. | 1.3 | 12 |
| 16 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 409-420. | 1.6 | 18 |
| 17 | Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 1-9. | 0.9 | 56 |
| 18 | Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with <i>CYP2B6</i> c.516G>T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4511-4518. | 1.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1755-1758. | 1.3 | 102 |
| 20 | Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1373-1383. | 1.4 | 13 |
| 21 | The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 174-180. | 1.2 | 29 |
| 22 | Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. <i>Infectious Diseases and Therapy</i> , 2016, 5, 65-71. | 1.8 | 19 |
| 23 | Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , 2016, 213, 1013-1017. | 1.9 | 40 |
| 24 | Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 861-873. | 1.6 | 51 |
| 25 | Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1041-1045. | 1.3 | 5 |
| 26 | Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567. | 2.9 | 89 |
| 27 | P187...A phase 1 study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Sexually Transmitted Infections</i> , 2015, 91, A78.1-A78. | 0.8 | 0 |
| 28 | Twenty years of boosting antiretroviral agents. <i>Aids</i> , 2015, 29, 2229-2233. | 1.0 | 9 |
| 29 | A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5. | 1.3 | 2 |
| 30 | Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6080-6086. | 1.4 | 19 |
| 31 | Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2816-2822. | 1.3 | 21 |
| 32 | Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 453-463. | 2.9 | 32 |
| 33 | Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1513-1516. | 1.3 | 9 |
| 34 | Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 555-561. | 1.3 | 35 |
| 35 | Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484. | 1.2 | 23 |
| 36 | Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19583. | 1.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19586. | 1.2 | 4 |
| 38 | Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915. | 1.3 | 13 |
| 39 | Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1642-1647. | 1.3 | 29 |
| 40 | Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013, 1, 4. | 1.8 | 26 |
| 41 | Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800. | 1.8 | 100 |
| 42 | The importance of drug-drug interactions in the DAA era. <i>Digestive and Liver Disease</i> , 2013, 45, S343-S348. | 0.4 | 32 |
| 43 | Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9. | 1.3 | 30 |
| 44 | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2213-2221. | 1.3 | 77 |
| 45 | Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111. | 1.3 | 131 |
| 46 | Darunavir: pharmacokinetics and drug interactions. <i>Antiviral Therapy</i> , 2008, 13, 1-13. | 0.6 | 19 |
| 47 | Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-907. | 0.6 | 32 |
| 48 | Darunavir: Pharmacokinetics and Drug Interactions. <i>Antiviral Therapy</i> , 2008, 13, 1-14. | 0.6 | 80 |
| 49 | Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 361-367. | 1.0 | 7 |
| 50 | Stopping antiretroviral therapy. <i>Aids</i> , 2007, 21, 1673-1682. | 1.0 | 63 |
| 51 | An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 468-473. | 1.0 | 75 |
| 52 | Drug Interactions in Infectious Diseases, 2nd edn. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 611-611. | 1.1 | 0 |
| 53 | The potential for interactions between antimalarial and antiretroviral drugs. <i>Aids</i> , 2005, 19, 995-1005. | 1.0 | 101 |
| 54 | Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 38-42. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-429. | 0.6 | 26 |
| 56 | Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2004, 9, 115-122. | 0.6 | 31 |
| 57 | Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf- α and Tnf-Receptor Levels, and on Metabolic Parameters. <i>Antiviral Therapy</i> , 2004, 9, 879-887. | 0.6 | 6 |
| 58 | Pharmacokinetic Drug Interactions with Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, S8-S14. | 0.9 | 50 |
| 59 | Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics. <i>Antiviral Therapy</i> , 2003, 8, 191-198. | 0.6 | 19 |
| 60 | Therapeutic drug monitoring in HIV infection: current status and future directions. <i>Aids</i> , 2002, 16, S5-S37. | 1.0 | 155 |
| 61 | Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection. <i>Clinical Pharmacokinetics</i> , 1999, 36, 289-304. | 1.6 | 253 |
| 62 | Protease Inhibitors in Patients with HIV Disease. <i>Clinical Pharmacokinetics</i> , 1997, 32, 194-209. | 1.6 | 239 |